Figure 1. Participant Flow in a Trial of Anticoagulation After Hip or Knee Arthroplasty.

^aA total of 1333 patients declined to have their data collected after enrollment; therefore, group allocation was not recorded. These patients were not included in any analysis and are not included in the tallies represented here.

^bPatients taking dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban, warfarin, or dual antiplatelet therapy preoperatively were excluded from the primary analysis.

^cPatients who opted out chose to withdraw after initially consenting and prior to 90-day follow-up.

^dOne additional patient who died recorded a venous thromboembolic event prior to death and therefore was not considered to be missing an outcome.